Cytokinetics, Incorporated (NASDAQ:CYTK) Holdings Lifted by Marshall Wace LLP

Marshall Wace LLP raised its holdings in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 14.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,153,313 shares of the biopharmaceutical company's stock after purchasing an additional 279,612 shares during the quarter. Marshall Wace LLP owned 1.82% of Cytokinetics worth $101,292,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Jones Financial Companies Lllp raised its position in Cytokinetics by 189.8% in the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 374 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in Cytokinetics during the fourth quarter worth about $29,000. AlphaQuest LLC grew its position in Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 1,135 shares during the period. J.Safra Asset Management Corp lifted its position in shares of Cytokinetics by 62.1% during the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company's stock valued at $83,000 after acquiring an additional 671 shares during the period. Finally, Blue Trust Inc. boosted its stake in shares of Cytokinetics by 85.8% during the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company's stock worth $86,000 after acquiring an additional 842 shares in the last quarter.

Cytokinetics Trading Up 1.8 %

NASDAQ CYTK traded up $0.68 during mid-day trading on Tuesday, hitting $38.61. The company's stock had a trading volume of 487,255 shares, compared to its average volume of 1,599,252. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a 52-week low of $32.74 and a 52-week high of $68.76. The stock's fifty day simple moving average is $42.55 and its two-hundred day simple moving average is $47.53. The firm has a market capitalization of $4.60 billion, a P/E ratio of -7.17 and a beta of 0.94.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to analysts' expectations of $14.26 million. Research analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 3,341 shares of Cytokinetics stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $43.27, for a total transaction of $144,565.07. Following the sale, the executive vice president now directly owns 64,434 shares in the company, valued at $2,788,059.18. The trade was a 4.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Fady Ibraham Malik sold 2,000 shares of the company's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $48.06, for a total transaction of $96,120.00. Following the completion of the sale, the executive vice president now directly owns 116,071 shares in the company, valued at $5,578,372.26. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 86,360 shares of company stock worth $3,567,425. 3.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CYTK has been the topic of a number of research analyst reports. Bank of America decreased their target price on Cytokinetics from $62.00 to $54.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 15th. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a report on Wednesday, January 22nd. They issued a "buy" rating and a $80.00 price target on the stock. Needham & Company LLC restated a "buy" rating and set a $72.00 price objective on shares of Cytokinetics in a research report on Tuesday, April 8th. Morgan Stanley set a $67.00 price target on Cytokinetics in a research report on Friday, March 7th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $78.00 price objective on shares of Cytokinetics in a research note on Thursday, April 10th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $81.63.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.